AlphaStocks
4.5
Weak

Cencora, Inc. (COR)

Health Care / Health Care Distributors

S&P 500

$308.46

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#677out of 1123 in Health Care

Is Cencora, Inc. a Good Investment in 2026?

Cencora, Inc. (COR) scores 4.5 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Buffett model rates Cencora, Inc. as Strong. However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 67%). Cencora, Inc. currently trades above its estimated fair value of $197, suggesting limited upside at current prices. Cencora, Inc. ranks #677 out of 1123 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E38.7ROE89.1Market Cap60BDiv Yield0.7

Estimated Fair Value

$197.1256% above

Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of 6% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 3.4 · Stalwart

Greenblatt

Caution

Bottom half (rank 67%)

Frequently Asked Questions

Is Cencora, Inc. (COR) a good investment?
Based on AlphaStocks' composite analysis, Cencora, Inc. (COR) scores 4.5 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of 6% may not justify the premium.
What is Cencora, Inc.'s Piotroski F-Score?
Cencora, Inc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is COR overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $197, COR appears overvalued. The stock currently trades 56% above its estimated fair value. Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of 6% may not justify the premium.
How does COR compare to other Health Care stocks?
Cencora, Inc. ranks #677 out of 1123 stocks in the Health Care sector, placing it in the top 60% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about COR?
AlphaStocks evaluates COR using five proven investment models. Piotroski: Attractive; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.5/10.

Similar Stocks

PARRBFAMNTAP

Compare COR with

COR vs PARRCOR vs BFAMCOR vs NTAP

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer